NMRA

Conviction 24HealthcareScan · Mon, Aug 10, 2026

NMRA$1.61-1.23%

ResistanceSupportVol 14

Vol MA14 947.31K

May 11May 28Jun 16Jul 6Jul 23Aug 10

Neumora Therapeutics, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.neumoratx.com ↗

Price1.61

Change-1.23%

Gap-1.84%

Rel volume6.70×

Avg volume853.29K

Avg $ vol1.37M

SMA 201.61

SMA 501.62

SMA 2002.17

Price vs 50-0.76%

Price vs 200-25.83%

MA stackbearish

50/200 cross—

Supertrendup · 1.34

RSI (14)49

MACD hist0.00

MACD cross—

Stoch %K / %D60 / 67

ADX (14)8

+DI / −DI21 / 23

RSI divergence—

MACD divergence—

ATR %+6.93%

ADR %5.50%

52w high3.59

52w low0.9145

From 52w high-55.15%

Above 52w low+76.05%

New 52w highNo

SqueezeOn · 19d

Bollinger width10.60%

%B0.49

Donchian pos57.69%

Donchian high1.72

Donchian low1.46

AVWAP (52w high)1.83

vs AVWAP high-12.07%

AVWAP (52w low)1.42

vs AVWAP low+13.41%

OBV trendDown

Chaikin MF (20)-0.04

Today vs 20d6.70×

Avg vol (14d)947.31K

Avg vol (20d)853.29K

Avg $ vol (20d)1.37M

Market cap—

RS 3m (vs SPY)-21.68%

RS 6m (vs SPY)-30.95%

RS line new highNo

Trend template1/8

Technical rank21.9

1 week-1.83%

1 month-4.17%

3 months-12.02%

6 months-24.06%

1 year-2.42%

YTD-3.01%

P/E-1.27

P/B4.27

P/S—

P/FCF-1.46

EPS-1.45

Div yield—

ROE-335.21%

ROA-153.97%

Debt/Eq1.60

Current5.09

EV/EBITDA-1.11

Gross margin—

Net margin—

Rev growth—

EPS growth2.81%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value267.9M

Revenue—

Net income-53.46M

Gross profit—

Free cash flow-206.56M

IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ExchangeNasdaq

Shares out185.28M

Employees92

ListedFri, Sep 15, 2023

Free float—

Float %—

Short interest—

Days to cover—

Short volume—

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction24 / 100

Pattern quality—

Tech rank21.9 / 100

Group rank86 / 100 · Leading

Status laneNo active setup

Setup direction—

Pattern family

Resistance1.83

Support1.40

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in NMRA

All disclosures →

No recent disclosed trades by Congress in NMRA. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in NMRA · 5 buys

Insider	Side	Shares	Value	Traded	Filed
Fust Matthew K Director · Stock Option (Right to Buy) · 2026-05-27	Grant	80K	$0	2026-05-27	2026-05-29
Burow Kristina Director · Stock Option (Right to Buy) · 2026-05-27	Grant	80K	$0	2026-05-27	2026-05-29
Ho Maykin Director · Stock Option (Right to Buy) · 2026-05-27	Grant	80K	$0	2026-05-27	2026-05-29
Piacquad David Director · Stock Option (Right to Buy) · 2026-05-27	Grant	80K	$0	2026-05-27	2026-05-29
Halawa Alaa Director · Stock Option (Right to Buy) · 2026-05-27	Grant	80K	$0	2026-05-27	2026-05-29

SEC filings

EDGAR filings in NMRA · 2 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.